Package insert adverse reaction data refer to pediatric patients.
Formulated product contains vitamin E. An additional daily dietary vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding.
- TRADE NAME: Koselugo (AstraZeneca)
- INDICATIONS: Pediatric patients 2 years of age and older with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
- CLASS: Kinase inhibitor, MEK inhibitor (mitogen-activated protein kinase (MEK1 and MEK2) inhibitor)
- HALF-LIFE: ~6.2 hours
- FDA APPROVAL DATE: 04/10/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A4 inhibitors, CYP3A4 inducers, Fluconazole - PREGNANCY: Based on animal studies, can cause fetal harm when administered to a pregnant woman.
- See adverse reactions attributed to class:
MEK inhibitor (mitogen-activated protein kinase (MEK1 and MEK2) inhibitor)
Please login to view the rest of this drug profile.
Page last updated 03/21/2024
